Evidence map›Paper›PMID 38863577›Full record

ArticleBrain communications2024

Single-molecule characterization of salivary protein aggregates from Parkinson's disease patients: a pilot study.

Martin Furlepa, Yu P Zhang, Evgeniia Lobanova, Lakmini Kahanawita, Giorgio Vivacqua, Caroline H Williams-Gray, David Klenerman

Abstract read
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Martin FurlepaDepartment of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.
Yu P ZhangDepartment of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.
Evgeniia LobanovaDepartment of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.ORCID https://orcid.org/0000-0002-7605-5820
Lakmini KahanawitaDepartment of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0PY, UK.
Giorgio VivacquaMicroscopic and Ultrastructural Anatomy Research Unit-Integrated Research Centre (PRABB), Campus Biomedico University of Rome, 00128 Rome, Italy.
Caroline H Williams-GrayDepartment of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0PY, UK.
David KlenermanDepartment of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.

Funding

Medical Research Council MR/X021874/1
6 · The paper itself

Abstract

Saliva is a convenient and accessible biofluid that has potential as a future diagnostic tool for Parkinson's disease. Candidate diagnostic tests for Parkinson's disease to date have predominantly focused on measurements of α-synuclein in CSF, but there is a need for accurate tests utilizing more easily accessible sample types. Prior studies utilizing saliva have used bulk measurements of salivary α-synuclein to provide diagnostic insight. Aggregate structure may influence the contribution of α-synuclein to disease pathology. Single-molecule approaches can characterize the structure of individual aggregates present in the biofluid and may, therefore, provide greater insight than bulk measurements. We have employed an antibody-based single-molecule pulldown assay to quantify salivary α-synuclein and amyloid-β peptide aggregate numbers and subsequently super-resolved captured aggregates using direct Stochastic Optical Reconstruction Microscopy to describe their morphological features. We show that the salivary α-synuclein aggregate/amyloid-β aggregate ratio is increased almost 2-fold in patients with Parkinson's disease (

Indexed as

amyloid-βParkinson’s diseasesalivasingle-molecule imagingα-synuclein

Identifiers

PMID38863577
PMCPMC11166177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.